$1,318.00
This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Definition
8 Patient segmentation
9 Symptoms
9 Risk factors
9 Diagnosis
11 TREATMENT
11 Chemotherapy
11 Corticosteroids
11 TKI therapy
11 Immunotherapy
12 Radiation therapy
12 Stem cell transplant
13 EPIDEMIOLOGY
16 MARKETED DRUGS
21 PIPELINE DRUGS
29 RECENT EVENTS AND ANALYST OPINION
29 Darzalex for ALL (June 6, 2022)
30 Tecartus for ALL (June 4, 2021)
32 Tecartus for ALL (May 19, 2021)
34 KEY UPCOMING EVENTS
35 KEY REGULATORY EVENTS
35 Kite Wins EMA Recommendation To Market Tecartus For Leukemia Patients
35 Jazz Pharmaceuticals’ Crisantaspase Among New Filings At EMA
35 New RMAT Designations Include Autolus’s CAR-T
36 Accord Receives CHMP Endorsements For Dasatinib
36 Xspray Pharma’s Dasynoc Under FDA Review
36 First Academic Sponsor On EMA’s PRIME Pledges Cheaper CAR-Ts
37 US FDA Cancels Panel Review Of Two ‘Delinquent’ Cancer Drug Accelerated Approvals
38 PROBABILITY OF SUCCESS
39 LICENSING AND ASSET ACQUISITION DEALS
39 Catalent Announces Exclusive Long-Term Supply Agreement With Erytech
39 Laurus Labs Buys Into Indian CAR-T Start-Up
39 Autolus On The Rise After Big Backing From Blackstone
41 REVENUE OPPORTUNITY
43 CLINICAL TRIAL LANDSCAPE
44 Sponsors by status
45 Sponsors by phase
46 Recent events
48 BIBLIOGRAPHY
50 APPENDIX
LIST OF FIGURES
15 Figure 1: Trends in incident cases of ALL, 2018–27
21 Figure 2: Overview of pipeline drugs for ALL in the US
21 Figure 3: Pipeline drugs for ALL, by company
22 Figure 4: Pipeline drugs for ALL, by drug type
22 Figure 5: Pipeline drugs for ALL, by classification
32 Figure 6: Tecartus for ALL (June 4, 2021): Phase I/II – ZUMA-3 (r/r Adults)
34 Figure 7: Key upcoming events in ALL
38 Figure 8: Probability of success in the hematologic pipeline
43 Figure 9: Clinical trials in ALL
43 Figure 10: Top 10 drugs for clinical trials in ALL
44 Figure 11: Top 10 companies for clinical trials in ALL
44 Figure 12: Trial locations in ALL
45 Figure 13: ALL trials status
46 Figure 14: ALL trials sponsors, by phase
LIST OF TABLES
14 Table 1: Incident cases of ALL, 2018–27
17 Table 2: Marketed drugs for ALL
23 Table 3: Pipeline drugs for ALL in the US
29 Table 4: Darzalex for ALL (June 6, 2022)
30 Table 5: Tecartus for ALL (June 4, 2021)
33 Table 6: Tecartus for ALL (May 19, 2021)
41 Table 7: Historical global sales, by drug ($m), 2017–21
42 Table 8: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!